PDS Biotechnology
PDSB
25 hedge funds and large institutions have $3.42M invested in PDS Biotechnology in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 9 closing their positions.
188% more capital invested
Capital invested by funds: $1.19M → $3.42M (+$2.23M)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.18% less ownership
Funds ownership: 11.27% → 11.09% (-0.18%)
11% less funds holding
Funds holding: 28 → 25 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$349K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$73.2K |
| 3 |
Two Sigma Advisers
New York
|
+$36.5K |
| 4 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
+$18.5K |
| 5 |
IGGA
Iron Gate Global Advisors
Nsl,
Utah
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$118K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$55K |
| 3 |
Millennium Management
New York
|
-$49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$28K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Victory Capital Management
San Antonio,
Texas
| – | -$4K | -4,272 | Closed |
|
27
BNP Paribas Financial Markets
Paris,
France
| – | -$1 | -2 | Closed |
|
28
Wells Fargo
San Francisco,
California
| – | -$1 | -1 | -1% |
|
|
JPLA
29
Joseph P. Lucia & Associates
Yorktown Heights,
New York
| – | +$28 | +25 | New |
|
30
Barclays
London,
United Kingdom
| – | +$41 | +37 | New |
|
PDSB Hedge Fund Activity: Q2 2020 in Review
25 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2020, worth a combined $3.42M — up 188% from $1.19M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PDSB and 6 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $349K. The largest seller was Worth Venture Partners, exiting entirely with an estimated $118K sold.
- 25 institutional investors held PDS Biotechnology (PDSB) as of Q2 2020, down from 28 in Q1 2020.
- Funds reported $3.42M of PDS Biotechnology stock for Q2 2020, up 188% quarter-over-quarter.
- 6 funds opened new PDS Biotechnology positions in Q2 2020 and 9 closed out, a net change of -3 holders.
- The largest PDS Biotechnology buyer in Q2 2020 was Renaissance Technologies, an estimated $349K added.
- The largest PDS Biotechnology seller in Q2 2020 was Worth Venture Partners, an estimated $118K sold.
Based on aggregated 13F filings for Q2 2020.